news
COVID-19 vaccine elicits high levels of neutralising antibodies in mice
A potential COVID-19 vaccine, made from a modified vesicular stomatitis virus with the SARS-CoV-2 Spike protein, was shown to protect mice against the virus.
List view / Grid view
Antibodies
news
Atomic-scale details of SARS-CoV-2 Spike protein from vaccine obtained
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
news
Five biomarkers revealed as indicators of COVID-19 patient survival
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
news
Screening process may enhance mAb drug development, say scientists
Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.
news
Nanoparticle COVID-19 vaccine elicits immune response in pre-clinical studies
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
news
Most antibodies targeting SARS-CoV-2 use specific immunoglobulin subtype
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
news
Protective antibodies identified for rare polio-like disease in children
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
news
Experimental CAR T therapy targets solid tumour cancer cells
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
news
Researchers reveal how a key human anti-HIV antibody prevents infection
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.
webinar
Drug repurposing approaches to fast track development of new therapies for COVID-19
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
whitepaper
ebook: The researcher’s guide to measuring binding affinity
Learn why measuring binding affinity is key to helping you decide the next steps in your research and what technologies are available to measure it.
news
N terminal domain of S protein revealed as antibody target for COVID-19
An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
whitepaper
Article: Immuno-oncology: Pushing the frontier of discovery through advanced high throughput flow cytometry
Immuno-oncology (IO) is increasingly prized as an effective therapy in cancer management.
news
Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures
Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
news
New antibody cocktail developed as potential therapy for COVID-19
Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.